Speak directly to the analyst to clarify any post sales queries you may have.
The cardiac biomarker market is advancing rapidly, driven by increasing clinical reliance on innovative diagnostics, evolving technologies, and ongoing shifts in regulatory and policy frameworks.
Market Snapshot: Cardiac Biomarker Market Growth and Trends
The cardiac biomarker market grew from USD 13.26 billion in 2024 to USD 14.41 billion in 2025. It is expected to continue growing at a CAGR of 9.33%, reaching USD 27.09 billion by 2032. This robust expansion is supported by both technological innovations and rising demand for precise, timely cardiovascular diagnostics across global healthcare ecosystems.
Scope & Segmentation
- Biomarker Types: Troponins, BNP & NT-proBNP, Myoglobin, Creatine Kinase (CK) MB
- Clinical Settings: Laboratory Testing, Point Of Care Testing
- Applications: Diagnosis (Acute Coronary Syndrome, Congestive Heart Failure, Myocardial Infarction), Prognosis, Risk Assessment
- End Users: Diagnostic Laboratories, Hospitals & Clinics, Research Institutes
- Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
- Covered Technologies & Companies: Innovative immunoassays, digital health integration, point-of-care analyzers; key industry participants include Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann-La Roche AG, bioMérieux SA, and others.
Key Takeaways
- ER and urgent care adoption of point-of-care cardiac biomarker testing is expanding, improving clinical response and decision timelines for high-risk patients.
- Next-generation immunoassays and multiplex platforms are enhancing sensitivity, enabling earlier and more precise cardiovascular diagnostics.
- Digital health integration, including mobile and connected devices, is transforming ongoing monitoring, especially for remote and at-risk populations.
- Collaborative innovation is increasing, with academic-industry partnerships driving both biomarker discovery and faster pathway validations.
- Market segmentation highlights diverse needs across end users, from assay reproducibility in labs to portability and speed in clinical settings.
Tariff Impact on Cardiac Biomarkers
Recent adjustments to United States tariffs on cardiac biomarker supply chains are prompting manufacturers to optimize production strategies and sourcing, with some shifting to local production and strategic regional partnerships. Distributors are adding alternative assay kits to portfolios to manage increased costs. Quality management remains a priority as rapid manufacturing scale-up responds to global sourcing shifts.
Cardiac Biomarker Market Methodology & Data Sources
This report applies a mixed-method research strategy. Qualitative insights were gathered from interviews with leading cardiologists, laboratory directors, regulatory specialists, and executive stakeholders. Quantitative analysis is grounded in peer-reviewed publications, official healthcare databases, and sector white papers, ensuring triangulated, reliable findings and robust segmentation models. All projections and scenarios undergo internal quality review.
Why This Report Matters
- Enables executive decision-making by providing actionable insights into competitive positioning and supply chain resilience.
- Equips stakeholders to anticipate and navigate regulatory, technological, and demographic market shifts for future-proofed investment planning.
- Offers a granular segmentation view, supporting targeted growth strategies in production, clinical adoption, and geographic expansion.
Conclusion
The cardiac biomarker market is being reshaped by technological progress, digital health integration, and global policy trends. Strategic insights from this report enable leaders to align with evolving demand patterns and position for sustainable market growth.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
List of Figures
Samples
LOADING...
Companies Mentioned
The key companies profiled in this Cardiac Biomarker market report include:- Abbott Laboratories
- Abcam plc
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- bioMérieux SA
- Danaher Corporation
- DiaSorin S.p.A.
- Epitope Diagnostics Inc.
- F. Hoffmann-La Roche AG
- Fujirebio Diagnostics Inc.
- Guangzhou Wondfo Biotech Co., Ltd.
- Hologic Inc.
- Johnson & Johnson Services, Inc.
- Life Diagnostics, Inc.
- LSI Medience Corporation
- Meridian Bioscience, Inc.
- Myriad RBM Inc.
- PerkinElmer, Inc.
- Quest Diagnostics Incorporated
- Quidel Corporation
- QuidelOrtho Corporation
- Randox Laboratories Limited
- Sekisui Medical Co., Ltd.
- Siemens Healthineers AG
- Singulex, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Tosoh Corporation
- Trinity Biotech plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | October 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 14.41 Billion |
| Forecasted Market Value ( USD | $ 27.09 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
